Does body-coil magnetic-resonance imaging have a role in the preoperative staging of patients with clinically localized prostate cancer?

Negative mpMRI Rules Out Extra-Prostatic Extension in Prostate Cancer before Robot-Assisted Radical Prostatectomy

Background: The accuracy of multi-parametric MRI (mpMRI) in the pre-operative staging of prostate cancer (PCa) remains controversial. Objective: The purpose of this study was to evaluate the ability of mpMRI to accurately predict PCa extra-prostatic extension (EPE) on a side-specific basis using a risk-stratified 5-point Likert scale. This study also aimed to assess the influence of mpMRI scan quality on diagnostic accuracy. Patients and Methods: We included 124 men who underwent robot-assisted RP (RARP) as part of the NeuroSAFE PROOF study at our centre. Three radiologists retrospectively reviewed mpMRI blinded to RP pathology and assigned a Likert score (1-5) for EPE on each side of the prostate. Each scan was also ascribed a Prostate Imaging Quality (PI-QUAL) score for assessing the quality of the mpMRI scan, where 1 represents the poorest and 5 represents the best diagnostic quality. Outcome measurements and statistical analyses: Diagnostic performance is presented for the binary classification of EPE, including 95% confidence intervals and the area under the receiver operating characteristic curve (AUC). Results: A total of 231 lobes from 121 men (mean age 56.9 years) were evaluated. Of these, 39 men (32.2%), or 43 lobes (18.6%), had EPE. A Likert score ≥3 had a sensitivity (SE), specificity (SP), NPV, and PPV of 90.4%, 52.3%, 96%, and 29.9%, respectively, and the AUC was 0.82 (95% CI: 0.77-0.86). The AUC was 0.76 (95% CI: 0.64-0.88), 0.78 (0.72-0.84), and 0.92 (0.88-0.96) for biparametric scans, PI-QUAL 1-3, and PI-QUAL 4-5 scans, respectively. Conclusions: MRI can be used effectively by genitourinary radiologists to rule out EPE and help inform surgical planning for men undergoing RARP. EPE prediction was more reliable when the MRI scan was (a) multi-parametric and (b) of a higher image quality according to the PI-QUAL scoring system.

Incremental value of high b value diffusion-weighted magnetic resonance imaging at 3-T for prediction of extracapsular extension in patients with prostate cancer: preliminary experience

PURPOSE

To investigate whether high b value diffusion-weighted imaging (DWI) contributes to the improvement of diagnostic ability of extracapsular extension (ECE) in prostate cancer (PC).

MATERIALS AND METHODS

Forty-three patients with PC underwent multiparametric MRI including DWI (b values: 0, 2000 s/mm²) at 3-T. Two radiologists assessed the presence of ECE and the diagnostic certainty degree using conventional diagnostic method by consensus. Tumor apparent diffusion coefficient (ADC, ×10^-3 mm²/s) was also measured. Independent predictors of ECE were identified among PSA, tumor ADC, Gleason score, and conventional MRI. ECE in patients with low diagnostic certainty by conventional MRI was further reevaluated using ADC cutoff value, and the results were combined with those of patients with high diagnostic certainty by conventional MRI (MRI + ADC method).

RESULTS

Tumor ADC was an independent predictor of ECE, and the ADC cutoff value was 0.72. The sensitivity, specificity, and accuracy of conventional MRI and MRI + ADC method in the diagnosis of ECE were 44, 92, and 72%, and 78, 96, and 88%, respectively. Among MRI findings leading to the judgement of low diagnostic certainty, broad tumor contact was most common (72% of the patients).

CONCLUSIONS

The addition of ADC obtained with high b value DWI at 3-T to conventional MRI improved the diagnostic ability of ECE.

Prostate MRI: can we do without DCE sequences in 2013?

Multiparametric MRI (mp-MRI) of the prostate currently provides stable and reproducible performances. The usefulness of dynamic contrast-enhanced (DCE) sequences is currently challenged, as they sometimes only confirm what has already been observed on diffusion-weighted imaging (DWI) and require the additional purchase of a contrast agent. Eliminating these sequences may help accelerate the use of MRI in addition to, or in lieu of, prostate biopsies in selected patients. However, many studies show that these sequences can detect lesions invisible on T2-weighted and diffusion-weighted images, better assess cancer extension and aggressiveness, and finally help detecting recurrence after treatment. We present the various applications of dynamic MRI and discuss the possible consequences of its omission from the current protocol.

Comparison of body-array MRI and Partin tables for predicting extracapsular prostate cancer

Objective:

The objective of this article is to evaluate the performance of magnetic resonance imaging (MRI) and Partin tables at predicting extracapsular disease (ECD) in men with prostate cancer.

Patients and methods:

We identified all patients who had a radical prostatectomy at our institution in 2008. MRI and Partin predictions of ECD were compared with the histopathological stage. Oncological outcome at one year was assessed by biochemical recurrence (BCR) (prostate-specific antigen (PSA) ≥ 0.4 ng/dl followed by another rise).

Results:

Staging and follow-up data were available for 69 of the 80 patients (86%) who had had radical prostatectomy. Thirty-five of 69 patients had a body-array MRI scan. MRI predicted ECD (≥ rT3) with a sensitivity of 41% and specificity of 69%. Partin tables (> 50% risk ECD) had a sensitivity of 81% and specificity of 54%. Of the 35 patients who had an MRI scan, 22 (63%) had ECD and nine (26%) had BCR. Of the 34 men who were not staged with an MRI, only 10 (29%) had ECD and four (12%) had BCR.

Conclusion:

MRI performed no better than Partin tables at predicting ECD. Furthermore, patients who did not have an MRI, because of favourable prognostic clinical variables, had a low risk of ECD and BCR. We question the role of body-array MRI for staging prostate cancer and recognise an urgent need for prospective evaluation of multiparametric MRI.

Diagnostic accuracy of surface coil magnetic resonance imaging at 1.5 T for local staging of elevated risk prostate cancer

INTRODUCTION

Preoperative prostate cancer stage predicts prognosis and affects treatment decisions. The purpose of this study was to estimate the sensitivity and specificity of surface coil magnetic resonance imaging (MRI) for prostate cancer stage using surgical pathologic data as the reference standard.

METHODS

High-risk patients (>/=cT3 or PSA >/=20 ng/mL or Gleason >/=8) and selected intermediate-risk patients (clinically bulky disease on exam or biopsy, cT2b/c, or Gleason 7 with >/=3 of 5 biopsy cores positive in a lobe) routinely received a pelvic MRI at our institution. The images of identified patients were reviewed by one radiologist who was blinded to clinical information. The radiologist reported presence or absence of tumour within each lobe of the prostate. Extraprostatic extension (EPE), seminal vesicle (SV) invasion and pelvic lymph node (PLN) metastasis were also reported. Radiological findings were compared with prostatectomy pathology reports.

RESULTS

During the study period, about 320 radical prostatectomies were performed. Of these, 32 had a preoperative surface coil pelvic MRI adequate for analysis. Pathologically, 53 of 64 (82.8%) prostate lobes contained tumour, 17 (26.6%) lobes had associated EPE, 12 (18.8%) had SV involvement and 7 (10.9%) sets of PLNs contained cancer. Magnetic resonance imaging sensitivity and specificity were, respectively, 94.3% and 81.8% for tumour location, 82.4% and 87.2% for EPE, 83.3% and 92.3% for SV invasion and 71.4% and 94.7% for PLN involvement.

INTERPRETATION

Surface coil MRI accurately stages many prostate cancer patients with elevated risk of extraprostatic disease. This mode of imaging may be reasonable at centres that do not have endorectal coil MRI.

Virtual in vivo biopsy map of early prostate neoplasm in TRAMP mice by MRI

BACKGROUND

The noninvasive, early detection of Prostate Intraepithelial Neoplasia (PIN), a precancerous neoplasia of the prostate, would be highly desirable. In our experiments, we used TRAMP mice to model PIN in the range of grade 1 through grade 4.

METHODS

Contrast enhanced pixel-by-pixel R1 mapping of the prostate was used to detect areas with the different prostate neoplasia grades. After anesthesia, Gd(ABE-DTTA) was injected I.V. A series of MRI images with varying TI were then acquired to create R1 maps in a 2 mm transversal tomographic slice that included the prostate. After euthanasia and the excision of the prostate, a 2 mm slice, corresponding to the tomographic slice, was selected and prepared for histological analysis. The microscopic sections of this slice were scanned and analyzed along with the R1 maps. The R1 values were normalized to that measured in muscle tissue in each individual mouse to account for possible variations among the mice in contrast agent uptake (R1(norm)). The R1(norm) values and the histological grades in the corresponding areas were correlated.

RESULTS

A significant difference was found between the R1(norm) values measured in areas with grade 1-2 versus those observed in areas with grades 3-4. Also, a significant correlation was found between the area size of the ROIs differentiated by MRI, and those determined by histology.

CONCLUSION

This method has the potential for early noninvasive detection of developing prostate cancer.

Pitfalls with MRI Evaluation of Prostate Cancer Detection

INTRODUCTION

To assess differences between MRI findings and histopathologically defined prostate cancer localization, we compared clinical results with mapping of radical prostatectomy specimens, and conducted a retrospective MRI cancer localization re-assessment by a urologist-technician after surgery.

METHODS

We performed MRI for a total of 37 suspected prostate cancer patients. Subsequently, all underwent retropubic radical prostatectomy after prostate biopsy for confirmation of the diagnosis. All the specimens were studied histopathologically with serial sectioning using a whole organ approach.

RESULTS

Of the 37 patients, 26 had positive MRI findings. All the surgical specimens contained cancerous lesions, and 23 had multiple foci. Twenty-four of the MRI-positive cases (92.3%) demonstrated coincidence of both MRI and histopathologically defined lesions. In the single focus cases, 78.6% (11/14) demonstrated exact coincidence, but in the multifocal cases there were no cases with exact coincidence of MRI and histopathological findings (0/23).

CONCLUSION

MRI evaluation cannot be considered an effective diagnostic tool in itself for detection of prostate cancers because sensitivity is far from satisfactory, especially in multi-focal cases.

Emerging techniques: Whole-body screening and staging with MRI

Strategies for screening or tumor staging include various modalities such as plain radiography, computed tomography (CT), MRI, and ultrasound. Technical innovations have created the feasibility to use MRI to image the entire body in a relatively short time-period. Whole-body MRI may play a potentially important role in evaluating for cancer or vascular disease. This article describes the rationale for using MRI to display the entire body, the techniques employed in whole-body MRI, possibilities and limitations, and summarizes first clinical results for screening and staging purposes.

Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer

PURPOSE OF REVIEW

Despite marked stage migration, approximately a third of patients with clinically organ-confined prostate cancer will have extracapsular extension on pathological analysis. To improve outcomes further, alternative modalities of determining extraprostatic disease must be investigated beyond the current clinical parameters of digital rectal examination, prostate-specific antigen, and Gleason score. In addition, discerning the location of tumor in patients with biochemical recurrence directly affects treatment choice. This review highlights developments in prostate cancer imaging that may improve staging and treatment planning for prostate cancer patients.

RECENT FINDINGS

Magnetic resonance imaging is most useful in the initial evaluation of men with prostate cancer. Its high specificity for the diagnosis of extracapsular extension is tempered by its low sensitivity. Positron emission tomography is used to assess regional and distant metastasis in many malignancies. Investigation into the most appropriate radiotracer for prostate cancer is paramount in any future applicability. The unique role of ProstaScint has been in evaluating patients with biochemical failure and in trying to discern metastasis before definitive therapy. The addition of spectroscopic imaging and nanoparticle infusion may lead to further improvements. Therefore, in differentiating local versus distant recurrence, appropriate interventions with radiotherapy or hormonal manipulation may be instituted.

SUMMARY

Magnetic resonance imaging, ProstaScint, and to some extent positron emission tomography are all relevant imaging modalities for the evaluation of patients with prostate cancer. Current technological advances in each arena are improving the accuracy of diagnosis. Despite their specific limitations, use in the proper clinical setting may provide essential information to improve management decisions and disease outcomes.

Whole-body magnetic resonance imaging

Whole-body magnetic resonance imaging is a fast and accurate modality for the detection of disease throughout the entire body. Technical improvements including the availability of different high image quality MR sequences, the remote movement of the imaging table, and the use of specialized surface coils have rendered whole-body screening with MRI a feasible method. In this article we describe underlying techniques and report on first clinical experiences of whole-body magnetic resonance imaging as a staging and screening method. Furthermore, advantages and limitations compared with whole-body imaging based on computed tomography are discussed.